Royce & Associates LP Buys Shares of 285,988 Compass Therapeutics, Inc. $CMPX

Royce & Associates LP bought a new stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 285,988 shares of the company’s stock, valued at approximately $1,536,000. Royce & Associates LP owned 0.16% of Compass Therapeutics at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Suvretta Capital Management LLC boosted its position in shares of Compass Therapeutics by 97.2% during the third quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after buying an additional 6,951,666 shares during the period. Monashee Investment Management LLC boosted its holdings in shares of Compass Therapeutics by 657.6% in the third quarter. Monashee Investment Management LLC now owns 1,250,000 shares of the company’s stock valued at $4,375,000 after purchasing an additional 1,085,000 shares during the period. M&T Bank Corp purchased a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $4,104,000. Blue Owl Capital Holdings LP boosted its holdings in shares of Compass Therapeutics by 33.8% in the fourth quarter. Blue Owl Capital Holdings LP now owns 3,466,525 shares of the company’s stock valued at $18,615,000 after purchasing an additional 875,000 shares during the period. Finally, CM Management LLC purchased a new stake in shares of Compass Therapeutics in the third quarter valued at approximately $525,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Compass Therapeutics in a report on Thursday, March 12th. Craig Hallum assumed coverage on Compass Therapeutics in a report on Friday, February 13th. They issued a “buy” rating and a $15.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 27th. Guggenheim reissued a “buy” rating and set a $12.00 price objective on shares of Compass Therapeutics in a report on Tuesday, March 24th. Finally, Citizens Jmp restated a “market outperform” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $13.60.

Compass Therapeutics Stock Down 1.2%

Compass Therapeutics stock opened at $2.38 on Friday. The business has a fifty day moving average of $3.81 and a two-hundred day moving average of $4.95. The firm has a market cap of $428.61 million, a P/E ratio of -5.80 and a beta of 0.79. Compass Therapeutics, Inc. has a twelve month low of $1.61 and a twelve month high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). Equities analysts expect that Compass Therapeutics, Inc. will post -0.44 earnings per share for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.